Breaking News

Q BioMed Enters $7.8M Financial Restructuring

Provides capital to bring FDA approved non-opioid, Strontium89 Chloride USP Injection drug to market.

By: Contract Pharma

Contract Pharma Staff

Q BioMed Inc., a commercial stage biotech company, has completed a financial restructuring of approximately $7.8 million with its lead investor, Yorkville Advisors Global (YA). This restructuring of debt and new capital will provide for the company to implement its full commercial plan as it brings its FDA approved non-opioid, Strontium89 Chloride USP Injection drug to market.  Denis Corin, QBioMed CEO said, “In addition to the rollout of our Strontium89 drug, this funding allows us to a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters